B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $64 to $67.
July 16, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Jason Gerberry maintains a Buy rating on Ionis Pharmaceuticals and raises the price target from $64 to $67.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to positively influence investor sentiment and drive short-term price appreciation for Ionis Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100